Abstract
As one of the leading causes of deaths worldwide, cancer is posing threat despite efforts being taken to develop effective anticancer drugs. There is an increase in number of chemotherapy treatments due to growing number of manifestations causing increasing toxicities of cytotoxic agents. Almost all the anticancer agents available till date have one or the other side effects. Topoisomerases are the attractive targets to develop effective anticancer agents. There has been development of many topoisomerase inhibitors till date and has shown good anticancer activity but their side effects outnumber their anticancer potential. Hence, there is an urgent need to develop effective therapeutic agents with fewer side effects. This review deals with design and development aspect of topoisomerase inhibitors as exciting novel anticancer agents. The emphasis has been laid in particular on the new potential heterocyles as TOP inhibitors in the field of medicinal chemistry. The review discusses about the topoisomerase poisons, TOP1 suppressors, TOP inhibitors and Dual TOP 1/2 inhibitors.
Keywords: Anticancer, topoisomerase types and inhibitors, structure activity relationship, topoisomerase inhibitors.
Mini-Reviews in Medicinal Chemistry
Title:Discovery and Development of Topoisomerase Inhibitors as Anticancer Agents
Volume: 16 Issue: 15
Author(s): Muthu K. Kathiravan, Anuj N. Kale and Shrikant Nilewar
Affiliation:
Keywords: Anticancer, topoisomerase types and inhibitors, structure activity relationship, topoisomerase inhibitors.
Abstract: As one of the leading causes of deaths worldwide, cancer is posing threat despite efforts being taken to develop effective anticancer drugs. There is an increase in number of chemotherapy treatments due to growing number of manifestations causing increasing toxicities of cytotoxic agents. Almost all the anticancer agents available till date have one or the other side effects. Topoisomerases are the attractive targets to develop effective anticancer agents. There has been development of many topoisomerase inhibitors till date and has shown good anticancer activity but their side effects outnumber their anticancer potential. Hence, there is an urgent need to develop effective therapeutic agents with fewer side effects. This review deals with design and development aspect of topoisomerase inhibitors as exciting novel anticancer agents. The emphasis has been laid in particular on the new potential heterocyles as TOP inhibitors in the field of medicinal chemistry. The review discusses about the topoisomerase poisons, TOP1 suppressors, TOP inhibitors and Dual TOP 1/2 inhibitors.
Export Options
About this article
Cite this article as:
Kathiravan K. Muthu, Kale N. Anuj and Nilewar Shrikant, Discovery and Development of Topoisomerase Inhibitors as Anticancer Agents, Mini-Reviews in Medicinal Chemistry 2016; 16 (15) . https://dx.doi.org/10.2174/1389557516666160822110819
DOI https://dx.doi.org/10.2174/1389557516666160822110819 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Adipose Triglyceride Lipase: A New Target in the Regulation of Lipolysis by Insulin
Current Diabetes Reviews Synthetic and Natural Protease Inhibitors Provide Insights into Parasite Development, Virulence and Pathogenesis
Current Medicinal Chemistry Advanced Echocardiographic Imaging of the Congenitally Malformed Heart
Current Cardiology Reviews Species Differences in Hepatocyte-Directed Gene Transfer: Implications for Clinical Translation
Current Gene Therapy Angina in Women without Obstructive Coronary Artery Disease
Current Cardiology Reviews Impact of Diabetes on Cardiac and Vascular Disease: Role of Calcium Signaling
Current Medicinal Chemistry Remediation of Cellular Hypoxic Damage by Pharmacological Agents
Current Pharmaceutical Design Mitochondrial Injury and Targeted Intervention in Septic Cardiomyopathy
Current Pharmaceutical Design Cardiotoxicity of Tyrosine-Kinase-Targeting Drugs
Cardiovascular & Hematological Agents in Medicinal Chemistry Can Unconventional Exercise be Helpful in the Treatment, Management and Prevention of Osteosarcopenic Obesity?
Current Aging Science Acetylation Control of Cancer Cell Metabolism
Current Pharmaceutical Design Antiarrhythmic Potential of Drugs Targeting the Cardiac Ryanodine Receptor Ca<sup>2+</sup> Release Channel: Case Study of Dantrolene
Current Pharmaceutical Design MicroRNA Therapeutics for Cardiac Regeneration
Mini-Reviews in Medicinal Chemistry Cardiac Cell Therapy and Bypass Surgery
Current Pharmaceutical Design Editorial (Thematic Issue: Managing Strategies for Diverse Diseases: Challenges from Bench to Bedside Translation in Successful Drug Discovery and Development (Part B))
Current Pharmaceutical Design Disease-Specific iPS Cell Models in Neuroscience
Current Molecular Medicine New Advances in the Field of Calcium Channel Antagonists: Cardiovascular Effects and Structure-Activity Relationships
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Cellular Therapy for Heart Failure
Current Cardiology Reviews Mitochondrial Complex I Deficiency in Humans
Current Genomics Recent Developments in Nanoparticle Based Targeted Delivery of Chemotherapeutics
Current Bioactive Compounds